Ibaraki, Japan

Saki Hasegawa

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: National Center of Neurology and Psychiatry, Nippon Shinyaku Company, Ltd.. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Saki Hasegawa. Retrieved from https://idiyas.com/inventor/saki-hasegawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Saki Hasegawa: Innovator in Antisense Nucleic Acid Technology

Introduction

Saki Hasegawa is a prominent inventor based in Ibaraki, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of antisense nucleic acids. Her work focuses on innovative solutions for genetic disorders, showcasing her dedication to advancing medical science.

Latest Patents

Hasegawa holds a patent for an "Antisense nucleic acid inducing skipping of exon 51." This invention provides a drug that facilitates highly efficient skipping of exon 51 in the human dystrophin gene. The specification details an antisense oligomer that effectively induces this skipping, offering potential therapeutic benefits for conditions related to dystrophin deficiency.

Career Highlights

Throughout her career, Hasegawa has worked with notable organizations, including Nippon Shinyaku Company, Ltd. and the National Center of Neurology and Psychiatry. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Hasegawa has collaborated with esteemed colleagues such as Yu Honda and Kaname Muchima. These partnerships have enriched her research and expanded the impact of her innovations in the scientific community.

Conclusion

Saki Hasegawa's contributions to antisense nucleic acid technology exemplify her commitment to improving human health through innovation. Her patent and collaborations highlight her role as a key figure in the advancement of genetic therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…